文章核心观点 - ABBV-383是一种针对B细胞成熟抗原(BCMA)的双特异性抗体T细胞募集剂,正在评估用于复发/难治性多发性骨髓瘤(r/r MM)的治疗[1][2] - CERVINO III期临床试验将评估ABBV-383单药疗法与标准可用疗法(SAT)在至少接受过两线以上治疗的r/r MM患者中的疗效、安全性和耐受性[1][2] - ABBV-383是一种由双价BCMA结合域和低亲和力CD3结合域组成的独特BCMA x CD3双特异性抗体T细胞募集剂,设计用于降低细胞因子释放并支持每4周一次的给药[5] BCMA作为治疗靶点 - BCMA高度表达于多发性骨髓瘤恶性浆细胞表面,是一个理想的治疗靶点[6][7] - BCMA在促进骨髓瘤细胞生长和抑制其凋亡(程序性细胞死亡)中起关键作用[7] 公司在肿瘤领域的承诺 - 公司致力于为患有难治性癌症的患者转变治疗标准,正在推进一个涵盖血液肿瘤和实体瘤的动态研发管线[7] - 公司专注于开发能够抑制癌细胞增殖或促进其消除的靶向治疗,包括抗体偶联药物(ADC)、免疫肿瘤学、双特异性和CAR-T平台[7] - 公司拥有一个广泛的肿瘤产品组合,正在评估20多种研究性药物,致力于为患者提供创新的治疗方案[8]

–   First indications of RINVOQ (upadacitinib) for pediatric patients two years of age and older1–   RINVOQ is now approved for eight indications across immune-mediated inflammatory diseases1 NORTH CHICAGO, Ill., June 4, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that RINVOQ® (upadacitinib) is indicated in the U.S. for the treatment of pediatric patients two years of age and older with active polyarticular juvenile idiopathic arthritis (pJIA) as well as psoriatic arthritis (PsA), provided they ...

文章核心观点 - 公司推出了"Refer a Friend"新功能,Allē会员可以邀请朋友加入,双方都可获得Allergan Aesthetics产品或治疗的优惠 [2][3][4] - 公司表示,口碑推荐是消费者选择美容服务提供商的重要因素,新功能可以帮助美容诊所获得新患者 [5] - Allē是美容行业首个提供会员积分的忠诚度计划,会员可以获得50多种非Allergan Aesthetics品牌的积分 [5] 公司概况 - Allergan Aesthetics是AbbVie公司旗下的美容品牌,提供面部注射、身体塑形、皮肤护理等产品和服务 [8] - AbbVie公司的使命是开发和提供创新的医疗解决方案,覆盖免疫学、肿瘤学、神经科学、眼科等领域 [9][10] 产品信息 - BOTOX®Cosmetic用于改善额头纹、鱼尾纹和眉间纹 [11] - JUVÉDERM®系列产品用于改善面部皱纹和塑形 [25][26][27][28][29] - SKINVIVE by JUVÉDERM®用于改善面颊肤质 [41] - CoolSculpting®和CoolSculpting®Elite用于消除腹部、腰部等部位的脂肪 [48] - DiamondGlow®是一种温和去角质并涂抹美容精华液的设备 [50] - SkinMedica®系列产品是美容类产品,不作医疗用途 [53][54]

AbbVie (ABBV) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending approval of Skyrizi (risankizumab) in the EU to treat adults with moderately to severely active ulcerative colitis (UC).The eligible patient population includes UC patients who have had an inadequate response, lost response, or were intolerant to either conventional or biologic therapy. The recommended treatment regime with AbbVie’s Skyriz ...

NORTH CHICAGO, Ill., June 3, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024. Robert A. Michael, president and chief operating officer, Scott T. Reents, executive vice president, chief financial officer, Jeffrey R. Stewart, executive vice president, chief commercial officer and Roopal Thakkar, M.D., senior vice president, chief medical officer, global therapeutics, will present at 9:00 a.m. Central time.A liv ...

The financial media does its best to keep you informed about what’s happening in the market. However, this has the effect of giving significant attention to a handful of leaders or laggards. That creates an opportunity for investors who have the patience to look for must-own overlooked stocks.  Overlooked stocks are not necessarily underperforming the market. In some cases, these stocks simply are slow and steady at a time when investors want to find the newest and brightest shiny object.  However, not ever ...

文章核心观点 - AbbVie公司的股价在最近一个交易日上涨3.2%,达到161.24美元,这可归因于交易量的显著增加[1] - 这一涨幅是由于公司宣布其重磅免疫药物Skyrizi在溃疡性结肠炎适应症上获得欧洲药品管理局委员会(CHMP)的正面意见[2] - 该公司预计在即将公布的季度财报中,每股收益将同比增长4.8%至3.05美元,但收入将同比下降10.1%至124.6亿美元[3] 行业和公司研究 行业分析 - AbbVie属于大型制药行业,该行业的公司包括强生公司(Johnson & Johnson)[6] - 强生公司最近一个交易日的股价上涨1%,达到146.67美元,但过去一个月下跌3.1%[6] - 强生公司即将公布的季度每股收益预计为2.73美元,同比下降2.5%[7] 公司分析 - AbbVie的Skyrizi药物自上市以来表现出色,得益于在新适应症上的批准[2] - 但AbbVie的季度每股收益预期在过去30天内略有下调,这通常不会带来股价上涨[5] - AbbVie目前的股票评级为中性(Zacks Rank 3)[6]

The positive opinion is based on results from two pivotal Phase 3 trials, INSPIRE and COMMAND, that evaluated the efficacy and safety of risankizumab in adults with moderately to severely active ulcerative colitis (UC)1,2In both trials, the primary endpoint of clinical remission (per Adapted Mayo Score*) and key secondary endpoints, including endoscopic improvement** and histologic-endoscopic mucosal improvement,† were met1,2UC is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affec ...

文章核心观点 - 公司的增长平台占据了公司业务的约80%,增长率达到中个位数[10] - 公司预计未来几年将实现高个位数的年收入增长[18] - 公司的创新能力和产品组合为其带来了长期的增长机会[15][16][17] 公司概况 - 公司是一家市值275亿美元的制药巨头[8] - 公司自2012年从雅培(Abbott)分拆独立上市以来,每年都在持续增加股息[7] - 公司的主要产品包括Skyrizi和Rinvoq,这两款产品在上市5年内销售额增长超过50%[12][13] - 公司预计这两款产品到2027年的销售额将超过270亿美元,年复合增长率达19%[14] 财务表现 - 公司2023年受到Humira专利到期的影响,预计EPS将下降19%[20] - 但从2024年开始,公司EPS增长预计将恢复到个位数,并在2026年达到12%[20] - 公司当前的市盈率为13.9倍,略高于10年平均水平13.2倍[19] - 结合4%的股息收益率和未来的增长预期,公司预计可以实现8-10%的年化总回报率[21] 发展前景 - 公司正在加强营销力度和战略合作,以更快地提高市场份额[17] - 公司正在积极拓展神经科学和肿瘤科等新领域,为未来发展带来新的增长动力[15][16] - 公司有望凭借创新能力和强大的产品组合,实现未来多年的双位数EPS增长[23]

New safety and efficacy data in heavily pre-treated patients with metastatic colorectal cancer (CRC), from a Phase 1 study of ABBV-400, a next-generation, potential best-in-class c-Met directed ADC. Data from a first-in-human study of ABBV-706, a potential best-in-class SEZ6 directed ADC, in small cell lung cancer (SCLC), high-grade central nervous system (CNS) tumors and high-grade neuroendocrine neoplasms (NENs). Data from the primary analysis of the Phase 2 LUMINOSITY trial evaluating Telisotuzumab ved ...